Clinical trial points to treatment advances for glioma patients for first time in decades
EurekAlert!,
In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression…
In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression…
In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression…
Listen with Speechify Register for free to listen to this article Thank you. Listen to this article using the player above.
In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression…
Susan Pandya, MD Vorasidenib (AG-881) monotherapy delivered superior progression-free survival (PFS) outcomes over placebo in…
Susan Pandya, MD Vorasidenib(AG-881) monotherapy elicited a statistically significant and clinically meaningful improvement in…
In Partnership With: Encouraging response rates to a dual-targeted regimen in patients with recurrent or refractory malignant…
The pandemic appears to have caused or contributed to a number of lasting changes in the way oncologists provide clinical care…
- Servier's first clinical data manuscript in glioma demonstrates a favorable safety profile and encouraging preliminary…
- Servier's first clinical data manuscript in glioma demonstrates a favorable safety profile and encouraging preliminary…
- Servier's first clinical data manuscript in glioma demonstrates a favorable safety profile and encouraging preliminary…
BOSTON, June 16, 2021 /PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to…
BOSTON, June 16, 2021 /PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to…
- Servier's first clinical data manuscript in glioma demonstrates a favorable safety profile and encouraging preliminary…
- Servier's first clinical data manuscript in glioma demonstrates a favorable safety profile and encouraging preliminary…
BOSTON, June 16, 2021 /PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to…
Servier Announces Promising Phase 1 Data for Vorasidenib in IDH Mutant Low-Grade Glioma Published in Clinical Cancer Research …
BOSTON, June 16, 2021 /PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to…
- Servier's first clinical data manuscript in glioma demonstrates a favorable safety profile and encouraging preliminary…
BOSTON, June 16, 2021 /PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to…